Clemson University

TUESDAY, Feb. 17, 2026 — A measles outbreak at a private college in southwest Florida is raising new concerns about how quickly the virus can spread. More than 40 cases have been reported at Ave Maria University , making it one of the largest measles outbreaks recorded on a U.S. college campus. Experts say the situation shows how measles, once mostly seen in kids, is becoming a growing threat for college students who are not vaccinated. Other campuses across the country have faced similar scares this year. In January, more than 80 students at Clemson University and Anderson University in South Carolina were quarantined after measles exposures. This month, about 4,000 people at the University of Wisconsin-Madison were notified of possible exposure, and students at the University of Florida were alerted after cases were linked to two classrooms. Most colleges require proof of measles vaccination, which is usually given as part of the MMR shot that protects against measles, mumps and rubella. However, many schools allow students to opt out for religious or personal reasons. There’s no longer a sense that measles on campus is unlikely, Dr. Sarah Van Orman , past president of the American College Health Association, told The New York Times . “For most of us, it’s not if we’ll get a case, it’s when,” she said. Before the measles vaccine became available in the 1960s, nearly all children got measles. About 450 people died from the disease each year, but survivors gained lifelong immunity early in life. Today’s college students grew up during a far different time. Thanks to widespread childhood vaccination, many were never exposed to measles, and some were never vaccinated. “We are now starting to see a group of individuals in their early 20s who are not protected,” Michael Osterholm , an infectious disease expert at the University of Minnesota, said. “They never had measles, they’ve never been vaccinated, and they’re in large enough numbers that we’re going to start seeing more outbreaks.” Ave Maria University asks its students to show proof of measles vaccination but allows exemptions under Florida law if students sign a waiver acknowledging the risks. The school says most people on campus are vaccinated, though it has not released exact numbers. Even small drops in vaccination rates can make a community vulnerable. College campuses are an “ideal” place for viruses like measles to spread, Dr. Jonathan Temte , a former chair of the U.S. Centers for Disease Control and Prevention (CDC)’s vaccine advisory committee, told The Times. While vaccinated people are far less likely to get sick, measles can still infect some whose immunity has weakened over time, though this is uncommon. What's more, colleges across the country are now reviewing vaccination records and updating outbreak plans in case more exposures occur. Some are also considering stricter vaccine rules. The outbreak comes as measles cases climb nationwide. Last year, the U.S. recorded 2,280 confirmed cases, the most since measles was declared eliminated in 2000. More than 700 cases have already been reported this year, with large clusters attributed to South Carolina and Florida. Public health experts warn that unless vaccination rates improve, college campuses may continue to see outbreaks that cause quarantines and put vulnerable students at risk. Sources The New York Times, Feb. 13, 2026

BOULDER, Colo., Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors. Mr. Martin brings proven success across all key commercial functions, including marketing, sales, commercial operations, market access, trade and business development. "We are thrilled to welcome Chris to our Board of Directors," said Kevin Koch, Ph.D., President and Chief Executive Officer. "His commercial expertise and launch leadership will be critical as we prepare for our first commercial launch in Becker muscular dystrophy and advance our cardiovascular asset to Phase 3. Prior to joining the Edgewise Board, Mr. Martin served as Chief Commercial Officer for Verona Pharma, which was acquired by Merck & Co. for approximately $10 billion in October of 2025. As CCO, Mr. Martin was responsible for building the commercial organization and launch strategy for the company's first product launch, Ohtuvayre® (ensifentrine). Prior, he served as Executive Director of Marketing at SK Life Science which is focused on developing novel therapeutics for central nervous system conditions. Mr. Martin was instrumental in developing the commercial and marketing strategy and the framework for launching their first commercial product, XCOPRI® (cenobamate tablets). Until its acquisition by Melinta Therapeutics, Mr. Martin was Head of Marketing at Cempra where he led the development and launch strategy for the company's first product, solithromycin. Prior to Cempra, he was at Salix Pharmaceuticals for 10 years in roles of increasing responsibility and led the Xifaxan® marketing team during the company's acquisition by Valeant Pharmaceuticals. Mr. Martin received a Bachelor of Science in Financial Management from Clemson University. About Edgewise Therapeutics Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X, Facebook and Instagram. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, Edgewise's product candidates and programs, including sevasemten, EDG-7500 and EDG-15400; statements regarding Edgewise's ability to commercialize sevasemten; statements regarding Edgewise's ability to advance its cardiovascular asset to Phase 3; and statements by Edgewise's President and Chief Executive Officer. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon Edgewise's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with Edgewise's limited operating history, its products being early in development and not having products approved for commercial sale; risks associated with Edgewise not having generated any revenue to date; Edgewise's ability to achieve objectives relating to the discovery, development and commercialization of its product candidates, if approved; Edgewise's need for substantial additional capital to finance its operations; Edgewise's substantial dependence on the success of sevasemten and EDG-7500; Edgewise's ability to develop and commercialize sevasemten, EDG-7500 and EDG-15400; risks related to Edgewise's clinical trials of its product candidates not demonstrating safety and efficacy; risks related to Edgewise's product candidates causing serious adverse events, toxicities or other undesirable side effects; the outcome of preclinical testing and early clinical trials not being predictive of the success of later clinical trials and the risks related to the results of Edgewise's clinical trials not satisfying the requirements of regulatory authorities; delays or difficulties in the enrollment and/or maintenance of patients in clinical trials; risks related to failure to capitalize on other indications or product candidates; risks related to competition; risks relating to interim, topline and preliminary data from Edgewise's clinical trials changing as more patient data becomes available; risks related to failure to develop a proprietary drug discovery platform; risks related to exposure to additional risk if we develop sevasemten and potential other programs in connection with other therapies; risks related to production of drugs by Edgewise's third-party manufacturers; risks related to changes in methods of product candidate manufacturing or formulation; risks related to not achieving adequate market acceptance; risks related to the patient population for our product candidates having a small patient population; risks related to the regulatory approval processes of domestic and foreign authorities being lengthy, time consuming and inherently unpredictable; risks relating to disruptions at the FDA, the SEC and other government agencies; risks relating to Edgewise's ability to attract and retain highly skilled executive officers and employees; Edgewise's ability to obtain and maintain intellectual property protection for its product candidates; Edgewise's reliance on third parties; risks related to future acquisitions or strategic partnerships; risks related to general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in documents that Edgewise files from time to time with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Edgewise assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-appoints-commercial-biotech-executive-christopher-martin-to-its-board-of-directors-302620999.html SOURCE Edgewise Therapeutics

THURSDAY, Feb. 6, 2025 -- Among children with high blood pressure (BP), there are racial and ethnic disparities in receipt of nutrition, lifestyle, and weight counseling, according to a study published online Jan. 29 in JAMA Network Open . Moonseong Heo, Ph.D., from Clemson University in South Carolina, and colleagues examined racial and ethnic disparities in receipt of nutrition, lifestyle, and weight counseling among patients with high BP at pediatric primary care visits in a post-hoc secondary analysis of the BP-CATCH study. Data were included from 2,677 participants from 59 practices: 21.1, 15.5, 41.5, and 20.9 percent were Black, Hispanic, White, and other race and ethnicity, respectively. The researchers found that the overall crude unadjusted rates of receiving counseling were 63.5, 57.6, 47.5, and 46.4 percent for nutrition, lifestyle, weight, and all counseling topics, respectively. Hispanic participants received significantly higher adjusted rates of nutrition counseling, lifestyle counseling, and all three counseling topics compared with the other three racial and ethnic groups (78.6, 69.3, and 52.1 percent, respectively). No significant differences were seen between any pairs of groups in the rates of receiving weight counseling. In general, these findings were consistent among participants without obesity; the only significant pairwise difference among those with obesity was that nutrition counseling rates were significantly different for White participants versus those reporting other race and ethnicity (68.3 versus 81.6 percent). "Our study also suggests that quality metrics should be stratified by demographic categories to highlight disparities and prevent worsening of inequities as efforts continue to improve and standardize care for all children," the authors write. One author disclosed ties to the biopharmaceutical industry. Abstract/Full Text Editorial Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.